Selling and Marketing Expense of Co-Diagnostics, Inc. from 30 Jun 2016 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate total amount of expenses directly related to the marketing or selling of products or services.
Summary
Co-Diagnostics, Inc. quarterly and annual Selling and Marketing Expense in USD history and change rate from 30 Jun 2016 to 30 Sep 2025.
  • Co-Diagnostics, Inc. Selling and Marketing Expense for the quarter ending 30 Sep 2025 was $568,937, a 46% decline year-over-year.
  • Co-Diagnostics, Inc. Selling and Marketing Expense for the twelve months ending 30 Sep 2025 was $2,654,349, a 49% decline year-over-year.
  • Co-Diagnostics, Inc. annual Selling and Marketing Expense for 2024 was $4,483,339, a 35% decline from 2023.
  • Co-Diagnostics, Inc. annual Selling and Marketing Expense for 2023 was $6,860,815, a 6.6% decline from 2022.
  • Co-Diagnostics, Inc. annual Selling and Marketing Expense for 2022 was $7,344,628, a 45% decline from 2021.
Source SEC data
View on sec.gov
Selling and Marketing Expense, Trailing 12 Months (USD)
Selling and Marketing Expense, Quarterly (USD)
Selling and Marketing Expense, YoY Quarterly Change (%)
Selling and Marketing Expense, Annual (USD)
Selling and Marketing Expense, YoY Annual Change (%)

Co-Diagnostics, Inc. Quarterly Selling and Marketing Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $2,654,349 $568,937 -$490,808 -46% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $3,145,157 $609,713 -$431,530 -41% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $3,576,687 $657,030 -$906,652 -58% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $4,483,339 $818,669 -$698,454 -46% 01 Oct 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
Q3 2024 $5,181,793 $1,059,745 -$844,650 -44% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $6,026,443 $1,041,243 -$691,723 -40% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $6,718,166 $1,563,682 -$142,649 -8.4% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $6,860,815 $1,517,123 +$186,775 +14% 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $6,674,040 $1,904,395 +$14,488 +0.77% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $6,659,552 $1,732,966 +$260,741 +18% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $6,398,811 $1,706,331 -$945,817 -36% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $7,344,628 $1,330,348 -$763,515 -36% 01 Oct 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
Q3 2022 $8,108,143 $1,889,907 -$2,363,184 -56% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $10,471,327 $1,472,225 -$4,381,088 -75% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $14,852,415 $2,652,148 +$1,454,602 +121% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $13,397,813 $2,093,863 -$1,114,102 -35% 01 Oct 2021 31 Dec 2021 10-K 16 Mar 2023 2022 FY
Q3 2021 $14,511,915 $4,253,091 +$3,454,617 +433% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $11,057,298 $5,853,313 +$5,463,122 +1400% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $5,594,176 $1,197,546 +$929,063 +346% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $4,665,113 $3,207,965 +$2,916,828 +1002% 01 Oct 2020 31 Dec 2020 10-K 24 Mar 2022 2021 FY
Q3 2020 $1,748,285 $798,474 +$536,114 +204% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $1,212,171 $390,191 +$138,115 +55% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $1,074,056 $268,483 +$12,380 +4.8% 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1
Q4 2019 $1,061,676 $291,137 -$455,084 -61% 01 Oct 2019 31 Dec 2019 10-K 25 Mar 2021 2020 FY
Q3 2019 $1,516,760 $262,360 +$82,103 +46% 01 Jul 2019 30 Sep 2019 10-Q 16 Nov 2020 2020 Q3
Q2 2019 $1,434,657 $252,076 +$108,186 +75% 01 Apr 2019 30 Jun 2019 10-Q/A 03 Nov 2020 2020 Q2
Q1 2019 $1,326,471 $256,103 +$160,840 +169% 01 Jan 2019 31 Mar 2019 10-Q 14 May 2020 2020 Q1
Q4 2018 $1,165,631 $746,221 +$626,431 +523% 01 Oct 2018 31 Dec 2018 10-K 30 Mar 2020 2019 FY
Q3 2018 $539,200 $180,257 +$63,179 +54% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $476,021 $143,890 +$18,264 +15% 01 Apr 2018 30 Jun 2018 10-Q 14 Aug 2019 2019 Q2
Q1 2018 $457,757 $95,263 +$31,046 +48% 01 Jan 2018 31 Mar 2018 10-Q 14 May 2019 2019 Q1
Q4 2017 $426,711 $119,790 01 Oct 2017 31 Dec 2017 10-K 01 Apr 2019 2018 FY
Q3 2017 $117,078 +$88,188 +305% 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018 2018 Q3
Q2 2017 $125,626 +$103,207 +460% 01 Apr 2017 30 Jun 2017 10-Q 10 Aug 2018 2018 Q2
Q1 2017 $64,217 01 Jan 2017 31 Mar 2017 10-Q 14 May 2018 2018 Q1
Q3 2016 $28,890 01 Jul 2016 30 Sep 2016 10-Q 14 Nov 2017 2017 Q3
Q2 2016 $22,419 01 Apr 2016 30 Jun 2016 10-Q 25 Aug 2017 2017 Q2

Co-Diagnostics, Inc. Annual Selling and Marketing Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $4,483,339 -$2,377,476 -35% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
2023 $6,860,815 -$483,813 -6.6% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2022 $7,344,628 -$6,053,185 -45% 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
2021 $13,397,813 +$8,732,700 +187% 01 Jan 2021 31 Dec 2021 10-K 16 Mar 2023 2022 FY
2020 $4,665,113 +$3,603,437 +339% 01 Jan 2020 31 Dec 2020 10-K 24 Mar 2022 2021 FY
2019 $1,061,676 -$103,955 -8.9% 01 Jan 2019 31 Dec 2019 10-K 25 Mar 2021 2020 FY
2018 $1,165,631 +$738,920 +173% 01 Jan 2018 31 Dec 2018 10-K 30 Mar 2020 2019 FY
2017 $426,711 +$304,606 +249% 01 Jan 2017 31 Dec 2017 10-K 01 Apr 2019 2018 FY
2016 $122,105 01 Jan 2016 31 Dec 2016 10-K 28 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.